PURE BIOSCIENCE, INC. 8-K

What Happened

• Pure Bioscience, Inc. (PURE) filed an 8‑K reporting the results of its Annual Meeting held on February 17, 2026. Of 111,886,485 shares outstanding as of the record date, 73,820,863 shares (65.97%) were represented.
• Stockholders elected all seven director nominees (Tom Y. Lee, Ivan Chen, Tom Myers, David M. Rendall, Robert Bartlett, Bernard Blotner, Darin Zehr), ratified Weinberg & Company, P.A. as auditor, approved executive compensation on a non‑binding advisory basis, and approved an amendment to increase authorized common shares.

Key Details

• Director elections: all seven nominees elected; individual approval ranged from 96.52% to 98.07% of votes cast. Example tallies: Tom Y. Lee — 59,860,307 For / 1,332,527 Withheld (12,628,029 broker non‑votes); Ivan Chen — 60,011,852 For / 1,180,982 Withheld (12,628,029 broker non‑votes).
• Auditor ratification: Weinberg & Company, P.A. ratified with 73,008,365 For, 137,649 Against, and 674,849 Abstentions (99.81% of votes cast).
• Executive compensation (advisory): approved with 58,428,196 For, 2,000,989 Against, 763,649 Abstentions, and 12,628,029 broker non‑votes (96.68% of votes cast).
• Amendment to Certificate of Incorporation: approved to increase authorized common stock from 200,000,000 to 250,000,000 shares. Vote: 71,472,843 For, 2,298,269 Against, 49,751 Abstentions; passed with approval from 63.87% of outstanding shares.

Why It Matters

• The board remains in place after the re‑election of all directors, which signals continuity in management and strategy.
• Ratification of the auditor confirms the company’s fiscal-year audit firm for FY ending July 31, 2026.
• The executive compensation proposal was approved on an advisory (non‑binding) basis, meaning shareholders expressed broad support but the vote does not legally change pay arrangements.
• Increasing authorized common shares to 250 million legally permits the company to issue more shares in the future, which can provide flexibility for financing or corporate actions but may also affect share count and potential dilution if new shares are issued.

Keywords: annual meeting, elected directors, ratified auditors, executive compensation, authorized shares increase, shareholder vote.